c19early.org COVID-19 treatment researchTixagevimab/cilgavimabTixagev../c.. (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

Loading...
 
More

Supplementary Data — Tixagevimab/cilgavimab reduced COVID-19 risk: real-time meta analysis of 17 studies

@CovidAnalysis, December 2024, Version 28V28
 
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ TACKLE Montgom.. (DB RCT) 0% 1.00 [0.32-3.07] death 6/452 6/451 Improvement, RR [CI] Treatment Control TACKLE Montgom.. (DB RCT) 50% 0.50 [0.13-1.98] death 3/452 6/451 TACKLE Montgom.. (DB RCT) 50% 0.50 [0.29-0.86] severe case 18/407 37/415 TACKLE Montgom.. (DB RCT) 57% 0.43 [0.25-0.75] hosp. 17/413 40/421 Lombardi -368% 4.68 [0.31-71.6] death 1/19 1/89 Immunocompromised OT​1 Lombardi 33% 0.67 [0.09-5.13] hosp. 1/19 7/89 Immunocompromised OT​1 Lombardi -24% 1.24 [0.90-1.70] viral+ 14/19 53/89 Immunocompromised OT​1 ACTIV-3-TICO Holland (DB RCT) 30% 0.70 [0.50-0.97] death 61/710 86/707 ACTIV-3-TICO Holland (DB RCT) 7% 0.93 [0.83-1.03] no recov. 710 (n) 707 (n) DisCoVeRy Hites (DB RCT) 40% 0.60 [0.28-1.23] death 12/123 16/103 DisCoVeRy Hites (DB RCT) -18% 1.18 [0.73-1.92] 7-point status 123 (n) 103 (n) DisCoVeRy Hites (DB RCT) 1% 0.99 [0.75-1.30] recov. time 123 (n) 103 (n) DisCoVeRy Hites (DB RCT) 9% 0.91 [0.70-1.19] no disch. 123 (n) 103 (n) STORM CHASER Levin (DB RCT) 42% 0.58 [0.34-1.00] symp. case 27/749 23/372 STORM CHASER Levin (DB RCT) 33% 0.67 [0.36-1.24] symp. case 23/749 17/372 PROVENT Levin (DB RCT) 86% 0.14 [0.01-2.98] death 0/3,441 2/1,731 PROVENT Levin (DB RCT) 82% 0.18 [0.09-0.35] symp. case 11/3,441 31/1,731 PROVENT Levin (DB RCT) 76% 0.24 [0.10-0.55] symp. case 8/3,441 17/1,731 Young-Xu (PSM) 64% 0.36 [0.18-0.73] death 1,733 (n) 6,354 (n) Immunocompromised Young-Xu (PSM) 69% 0.31 [0.18-0.53] cases/death/hosp. 17/1,733 206/6,354 Immunocompromised Young-Xu (PSM) 87% 0.13 [0.02-0.99] hosp. 1,733 (n) 6,354 (n) Immunocompromised Young-Xu (PSM) 66% 0.34 [0.13-0.87] cases 1,733 (n) 6,354 (n) Immunocompromised Ollila 76% 0.24 [0.01-5.61] death 0/25 1/12 Immunocompromised Ollila 90% 0.10 [0.01-0.78] cases 0/25 3/12 Immunocompromised Kertes 92% 0.08 [0.01-0.54] death/hosp. 1/825 63/4,299 Immunocompromised Kertes 47% 0.53 [0.32-0.85] cases 29/825 308/4,299 Immunocompromised Najjar-Debbiny 59% 0.41 [0.19-0.89] hosp. 72/703 377/2,812 Immunocompromised Najjar-Debbiny 25% 0.75 [0.58-0.96] cases 72/703 377/2,812 Immunocompromised Kaminski 92% 0.08 [0.01-1.16] death 1/333 2/97 Immunocompromised Kaminski 96% 0.04 [0.01-0.24] ICU 2/333 6/97 Immunocompromised Kaminski 95% 0.05 [0.01-0.16] hosp. 4/333 11/97 Immunocompromised Kaminski 99% 0.01 [0.06-0.20] symp. case 41/333 42/97 Immunocompromised Al Jurdi 86% 0.14 [0.01-2.75] death 0/222 3/222 Immunocompromised Al Jurdi 83% 0.17 [0.02-1.37] hosp. 1/222 6/222 Immunocompromised Al Jurdi 66% 0.34 [0.18-0.66] cases 11/222 32/222 Immunocompromised Sindu (PSM) -1% 1.01 [0.14-7.21] death 2/17 2/17 Immunocompromised Sindu (PSM) -96% 1.96 [0.18-21.6] ventilation n/a n/a Immunocompromised Sindu (PSM) -210% 3.10 [0.32-29.8] ICU n/a n/a Immunocompromised Sindu (PSM) 53% 0.47 [0.16-1.40] hosp. n/a n/a Immunocompromised Sindu 29% 0.71 [0.46-1.11] symp. case 24/203 57/343 Immunocompromised Din 19% 0.81 [0.32-2.04] hosp. 5/23 11/41 Immunocompromised Desai 12% 0.88 [0.33-2.35] hosp. 391 (n) 391 (n) Desai -35% 1.35 [0.87-2.10] cases 391 (n) 391 (n) Solera 26% 0.74 [0.32-1.60] severe case 7/156 283/1,819 Bes-Berlandier -10% 1.10 [0.37-3.31] progression 3/14 15/77 Tixagevimab/cilgavimab COVID-19 outcomes c19early.org December 2024 1 OT: comparison with other treatment Favors tixagevimab/ci.. Favors control
Figure S1. All outcomes.
Loading..
Figure S2. Comparison of results for RCTs versus observational studies. For COVID-19 treatments, there is no significant difference between the results of RCTs and observational studies. Observational studies do not systematically over or underestimate efficacy. For high-cost treatments, there is a non-significant trend towards RCTs showing greater efficacy.
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit